Vera Therapeutics is expected to report a Q3 2026 consensus revenue of $3.90 million and an EPS loss of -$1.72, with the stock currently trading around $30.98 against an average analyst price target of $76.86.
Investors are primarily focused on the commercial launch performance of TRUTAKNA (atacicept), the company's lead drug for IgA nephropathy, which received accelerated FDA approval in July 2026.
This report marks a critical transition as the company records its first meaningful product revenue following years as a pre-commercial organization. Analysts are also looking for final efficacy results from the Phase 3 ORIGIN trial, expected this quarter to support the submission of a supplemental Biologics License Application (sBLA) for full regulatory approval.